PT1670489E - Utilização de xénon com hipotermia para o tratamento de asfixia neonatal - Google Patents

Utilização de xénon com hipotermia para o tratamento de asfixia neonatal Download PDF

Info

Publication number
PT1670489E
PT1670489E PT04768829T PT04768829T PT1670489E PT 1670489 E PT1670489 E PT 1670489E PT 04768829 T PT04768829 T PT 04768829T PT 04768829 T PT04768829 T PT 04768829T PT 1670489 E PT1670489 E PT 1670489E
Authority
PT
Portugal
Prior art keywords
hypothermia
xenon
neonatal asphyxia
treating neonatal
asphyxia
Prior art date
Application number
PT04768829T
Other languages
English (en)
Portuguese (pt)
Inventor
Mervyn Maze
Nicholas Peter Franks
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34436835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1670489(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0323861A external-priority patent/GB0323861D0/en
Priority claimed from GB0418539A external-priority patent/GB0418539D0/en
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of PT1670489E publication Critical patent/PT1670489E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
PT04768829T 2003-10-10 2004-10-11 Utilização de xénon com hipotermia para o tratamento de asfixia neonatal PT1670489E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0323861A GB0323861D0 (en) 2003-10-10 2003-10-10 Use
GB0418539A GB0418539D0 (en) 2004-08-19 2004-08-19 Use

Publications (1)

Publication Number Publication Date
PT1670489E true PT1670489E (pt) 2008-02-28

Family

ID=34436835

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04768829T PT1670489E (pt) 2003-10-10 2004-10-11 Utilização de xénon com hipotermia para o tratamento de asfixia neonatal

Country Status (13)

Country Link
US (1) US7390508B2 (https=)
EP (1) EP1670489B1 (https=)
JP (1) JP4880466B2 (https=)
AT (1) ATE380554T1 (https=)
AU (1) AU2004280118B2 (https=)
BR (1) BRPI0415232A (https=)
CA (1) CA2538104C (https=)
DE (1) DE602004010691T2 (https=)
DK (1) DK1670489T3 (https=)
ES (1) ES2298815T3 (https=)
MX (1) MXPA06003471A (https=)
PT (1) PT1670489E (https=)
WO (1) WO2005034966A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034966A1 (en) * 2003-10-10 2005-04-21 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
EP2244783B1 (en) 2008-01-22 2019-12-18 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
AU2014277860A1 (en) * 2008-01-22 2015-01-22 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
EP2427243A4 (en) 2009-05-05 2012-11-21 Vapogenix Inc NEW FORMULATIONS OF VOLATILE ANESTHETICS AND METHOD OF ADMINISTRATION
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
CA3132914C (en) 2013-03-15 2023-11-07 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
US10792305B2 (en) 2015-06-23 2020-10-06 Nobilis Therapeutics, Inc. Therapeutic immune modulation using noble gas compositions
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE19933704A1 (de) 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
JP2003530185A (ja) * 2000-03-31 2003-10-14 インナークール セラピーズ， インコーポレイテッド 医療法
WO2005034966A1 (en) * 2003-10-10 2005-04-21 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia

Also Published As

Publication number Publication date
BRPI0415232A (pt) 2006-12-12
DK1670489T3 (da) 2008-01-07
AU2004280118B2 (en) 2009-01-15
US7390508B2 (en) 2008-06-24
ES2298815T3 (es) 2008-05-16
AU2004280118A1 (en) 2005-04-21
CA2538104A1 (en) 2005-04-21
CA2538104C (en) 2013-12-10
EP1670489A1 (en) 2006-06-21
JP2007508284A (ja) 2007-04-05
JP4880466B2 (ja) 2012-02-22
MXPA06003471A (es) 2006-06-14
EP1670489B1 (en) 2007-12-12
US20070104796A1 (en) 2007-05-10
DE602004010691T2 (de) 2008-12-04
WO2005034966A1 (en) 2005-04-21
ATE380554T1 (de) 2007-12-15
DE602004010691D1 (de) 2008-01-24

Similar Documents

Publication Publication Date Title
TW200640488A (en) Extending time to disease progression or survival in cancer patients
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
NZ591312A (en) Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2007128761A3 (de) Verwendungen von dpp iv inhibitoren
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
MXPA04009929A (es) Tratamiento de la gastroparesis.
PT1670489E (pt) Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
WO2005002617A3 (fr) Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
EA200801890A1 (ru) Средство для лечения шума в ушах
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
WO2005120643A8 (en) Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates